[The antifungal agent naftifin. Placebo-controlled therapeutic comparison in tinea pedis].
The antimycotic efficacy of Naftifine was compared with that of placebo in a double-blind randomized trial in 60 patients with Tinea pedum proved by culture and microscopic examination. Naftifine was significantly superior to placebo concerning the number of mycologically cured patients as well as the clinical response to therapy. At the end of the study all patients were cured by Naftifine, whereas no patient of the placebo group showed an improvement.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000499:Allylamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000588:Amines / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D014008:Tinea Pedis / Q000188:drug therapy*
D000588:Amines; D000935:Antifungal Agents; D005782:Gels; D000499:Allylamine; C029178:naftifine
Antimykotikum Naftifin. Placebo-kontrollierter Therapievergleich bei Tinea pedum.